Clinical Trial Detail

NCT ID NCT02234180
Title Study of Adjuvant Regorafenib vs Placebo in Patients With Node Positive Esophageal Cancer That Completed Pre-operative Therapy
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements no
Sponsors Academic and Community Cancer Research United
Indications

gastroesophageal junction adenocarcinoma

esophagus adenocarcinoma

Therapies

Regorafenib

Age Groups: adult

No variant requirements are available.